The global embolization in interventional oncology market is estimated to reach nearly US$ 5.6 Billion in 2021, expanding at a CAGR of 16.9% from 2017 to 2021.
Browse Embolization in Interventional Oncology Market by Procedure Type (Bland Embolization, Radioembolization, Transarterial Chemoembolization) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/embolization-interventional-oncology-market/
Embolization is a minimally invasive therapy to block a blood vessel. It is commonly used to stop bleeding as well as to stop blood flow to a tumor in order to shrink it or in preparation for removal. Embolization is a procedure that injects substances to try to block or reduce the blood flow to cancer cells. It is an option for some patients with tumors that cannot be removed by surgery, and where tumors are too large to be treated with ablation. Bland embolization includes delivery of sub-millimeter microparticles through a catheter inserted in the groin and advanced into the liver under X-ray guidance to get access into the tumor vasculature. Radioembolization technique combines embolization with radiation therapy and is sometimes known as Selective internal radiation therapy (SIRT) or trans-arterial radioembolization. It includes microspheres loaded with a radioactive isotope (Yttrium-90) are injected into the blood vessels feeding a tumor and deliver a lethal dose of radiation into the vessels feeding the tumor thereby causing cell death. Chemoembolization or trans-arterial chemoembolization (or TACE) combines embolization with chemotherapy. TACE includes delivery of intra-arterial chemotherapy to the liver through a catheter in combination with embolic material to produce ischemia. Drug eluting bead chemoembolization (DEB-TACE) includes delivery of microparticles that are themselves loaded with the chemotherapy agent – doxorubicin – and allow for prolonged elution into the tumor microvessels.
The global embolization in interventional oncology market report estimates the market size (Revenue USD million – 2014 to 2021) based on embolization procedure type (bland embolization, radioembolization, transarterial chemoembolization), by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2017 to 2021). The global embolization in interventional oncology market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating in the global embolization in interventional oncology market and profiled in this report include Blockade, Braile Biomedica, BTG International, CeloNova BioSciences, Inc., Cook Medical, Covidien, Depuy Synthes, Merit Medical Systems, Inc., Penumbra, Sequent Medical, Stryker, and Terumo.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/embolization-interventional-oncology-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
Email: [email protected]